ArticleCardiovascular diabetology2025
Associations between steatotic liver disease subtypes and incident atrial fibrillation in young adults: a nationwide cohort study.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correspondence to editorial 1 on "Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis".Clinical and molecular hepatology · 2026Article
- When Atrial Fibrillation Meets Alcoholic Liver Cirrhosis: Can Direct Oral Anticoagulants Bridge the Therapeutic Gap?Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND/
aimMetabolic dysfunction is emerging as a significant risk factor for atrial fibrillation (AF) and serves as a foundational component of both metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with moderate alcohol intake (MetALD). As the prevalence of steatotic liver disease (SLD) rises among young adults, clarifying its association with AF in this population has become a clinical priority. Accordingly, we aimed to investigate the link between different SLD subtypes and the risk of incident AF in young adults.
methodsIn this nationwide cohort study, we analyzed data from the Korean National Health Insurance Service and included individuals aged 20-39 years who underwent health screening examinations between 2009 and 2012. The participants were categorized into either the non-SLD group or the SLD group, which was defined by a fatty liver index ≥ 30. SLD was further subclassified into MASLD, MetALD, and alcohol-associated liver disease (ALD) for analysis. The risk of incident AF was evaluated using Cox proportional hazards models.
resultsA total of 6,375,710 young adults (mean age 30.9 years; 59.4% male) were included, with a median follow-up period of 10.6 years. The prevalence of SLD was 27.8%, which included cases of MASLD (81.7%), MetALD (13.5%), and ALD (4.7%). The risk of incident AF was significantly elevated in individuals with SLD, with progressive increases across MASLD, MetALD, and ALD subtypes. Compared with those of the non-SLD group, the adjusted hazard ratios for AF were 1.09 (95% confidence interval [CI], 1.05-1.31) in the MASLD group, 1.29 (95% CI, 1.22-1.36) in the MetALD group, and 1.52 (95% CI, 1.41-1.65) in the ALD group.
conclusionSLD is associated with new-onset AF, with a progressively increased risk across MASLD, MetALD, and ALD subtypes in young adults. Given the modifiable nature of these risks, early interventions are essential to prevent long-term cardiovascular complications and reduce the future disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.